Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
$38.88
-8.8%
$33.13
$0.94
$79.02
$273.91M-6.1351,364 shs29,435 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
0.00%-11.56%+15.13%+49.54%+3,434.55%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
2.5685 of 5 stars
3.62.00.00.03.52.50.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
3.13
Buy$83.25114.12% Upside

Current Analyst Ratings Breakdown

Latest DRUG Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/19/2025
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$85.00
7/2/2025
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight
(Data available from 8/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
N/AN/AN/AN/A$0.92 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
-$2.06M-$0.93N/AN/AN/AN/A-20.96%-20.66%N/A

Latest DRUG Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q3 2025
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
-$0.59-$0.53+$0.06-$0.53N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
N/A
86.64
86.64

Institutional Ownership

CompanyInstitutional Ownership
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
40.52%

Insider Ownership

CompanyInsider Ownership
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
42.66%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
N/A7.04 million4.04 millionNot Optionable

Recent News About These Companies

Bright Minds Biosciences to Present at Upcoming Conferences
Equities Analysts Issue Forecasts for DRUG FY2025 Earnings
FY2025 EPS Estimates for DRUG Raised by Cantor Fitzgerald

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Bright Minds Biosciences stock logo

Bright Minds Biosciences NASDAQ:DRUG

$38.88 -3.75 (-8.80%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$38.50 -0.38 (-0.98%)
As of 08/29/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.